Prognostic value of nuclear DNA quantification and cyclin A expression in epithelial ovarian carcinoma

Eur J Obstet Gynecol Reprod Biol. 2008 Jan;136(1):110-5. doi: 10.1016/j.ejogrb.2006.10.008. Epub 2006 Dec 8.

Abstract

Objective: To investigate the correlation of DNA ploidy, S-phase fraction (SPF) and the expression of cyclin A to the clinical prognostic factors in patients with epithelial ovarian cancer.

Study design: A prospective analysis was performed on 46 ovarian tumor patients. The DNA ploidy and SPF were determined by flow cytometry and the expression of cyclin A was measured by immunohistochemical staining.

Results: Compared with benign and borderline tumors, the malignant tumors expressed higher levels of cyclin A (P=0.007), more aneuploid cells (P=0.018) and higher SPF (P=0.015). With regard to DNA ploidy and the clinical prognostic factors, aneuploid cells increased with tumor grade (P=0.011), the disease stage (P=0.009) and residual volume (P=0.001). When residual tumor was more than 2 cm, the expression of cyclin A was increased (P=0.043). Three-year survival was low for patients with tumors expressing cyclin A in over 10% of cells (P=0.003).

Conclusions: The data suggest that the assessment of the DNA ploidy, SPF and the expression of cyclin A may provide important information for predicting the prognosis of epithelial ovarian cancer.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Biomarkers / metabolism
  • Cyclin A / metabolism*
  • DNA, Neoplasm / analysis*
  • Female
  • Flow Cytometry
  • Genetic Markers
  • Humans
  • Immunohistochemistry
  • Kaplan-Meier Estimate
  • Neoplasm Staging
  • Ovarian Neoplasms / genetics*
  • Ovarian Neoplasms / metabolism
  • Ovarian Neoplasms / mortality
  • Ploidies*
  • Prognosis
  • Prospective Studies
  • S Phase*
  • Survival Rate

Substances

  • Biomarkers
  • Cyclin A
  • DNA, Neoplasm
  • Genetic Markers